miR-125a-3p targets MTA1 to suppress NSCLC cell proliferation, migration, and invasion

Hong Zhang1, Xiaoxia Zhu2, Na Li1

  • 1Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.

Insights

MicroRNA-125a-3p suppresses non-small-cell lung cancer (NSCLC) by targeting metastasis-associated gene 1 (MTA1). This discovery offers new therapeutic strategies for NSCLC by targeting the miR-125a-3p/MTA1 axis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gene Regulation

Background:

  • Metastasis-associated gene 1 (MTA1) plays a crucial role in non-small-cell lung cancer (NSCLC) progression, influencing cell growth, metastasis, and survival.
  • MicroRNAs (miRNAs) are key regulators of gene expression, mediating post-transcriptional silencing through interactions with target messenger RNAs (mRNAs).

Purpose of the Study:

  • To identify specific miRNAs capable of suppressing malignancy in NSCLC by targeting MTA1.
  • To elucidate the functional role and molecular mechanisms of the identified miRNA-MTA1 interaction in NSCLC pathogenesis.

Main Methods:

  • Quantitative RT-PCR and western blotting were used to analyze MTA1 expression in NSCLC cell lines and patient tissues.
  • Luciferase reporter assays confirmed the direct regulatory relationship between candidate miRNAs and MTA1.
  • Cell proliferation, migration, and invasion assays (MTT, EDU, colony formation, wound-healing, transwell) assessed the functional impact of miRNA modulation.

Main Results:

  • miR-125a-3p was identified as a direct regulator of MTA1 in NSCLC cells, confirmed by luciferase assays.
  • MTA1 expression was found to be inversely correlated with miR-125a-3p levels in NSCLC tissues.
  • Overexpression of miR-125a-3p significantly inhibited NSCLC cell proliferation, migration, and invasion by down-regulating MTA1.

Conclusions:

  • The miR-125a-3p/MTA1 axis plays a critical role in suppressing NSCLC progression.
  • miR-125a-3p acts as a tumor suppressor in NSCLC by targeting MTA1, inhibiting cell proliferation, migration, and invasion.
  • This axis represents a potential novel therapeutic target for NSCLC treatment.